Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide

Kok Fei Chan, Benjamin S. Gully, Stephanie Gras, Dennis X. Beringer, Lars Kjer-Nielsen, Jonathan Cebon, James McCluskey, Weisan Chen, Jamie Rossjohn

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Human leukocyte antigen (HLA)-I molecules generally bind short peptides (8-10 amino acids), although extended HLA-I restricted peptides (>10 amino acids) can be presented to T cells. However, the function of such extended HLA-I epitopes in tumour immunity, and how they would be recognised by T-cell receptors (TCR) remains unclear. Here we show that the structures of two distinct TCRs (TRAV4+TRAJ21+-TRBV28+TRBJ2-3+ and TRAV4 + TRAJ8+-TRBV9+TRBJ2-1+), originating from a polyclonal T-cell repertoire, bind to HLA-B∗07:02, presenting a 13-amino-acid-long tumour-associated peptide, NY-ESO-160-72. Comparison of the structures reveals that the two TCRs differentially binds NY-ESO-160-72-HLA-B∗07:02 complex, and induces differing extent of conformational change of the NY-ESO-160-72 epitope. Accordingly, polyclonal TCR usage towards an extended HLA-I restricted tumour epitope translates to differing TCR recognition modes, whereby extensive flexibility at the TCR-pHLA-I interface engenders recognition.

LanguageEnglish
Article number1026
Number of pages13
JournalNature Communications
Volume9
Issue number1
DOIs
Publication statusPublished - 1 Dec 2018

Keywords

  • adaptive immunity
  • antigen processing and presentation
  • tumour immunology
  • x-ray crystallography

Cite this

Chan, Kok Fei ; Gully, Benjamin S. ; Gras, Stephanie ; Beringer, Dennis X. ; Kjer-Nielsen, Lars ; Cebon, Jonathan ; McCluskey, James ; Chen, Weisan ; Rossjohn, Jamie. / Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide. In: Nature Communications. 2018 ; Vol. 9, No. 1.
@article{842958a193d649959c98349f005e0c8b,
title = "Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide",
abstract = "Human leukocyte antigen (HLA)-I molecules generally bind short peptides (8-10 amino acids), although extended HLA-I restricted peptides (>10 amino acids) can be presented to T cells. However, the function of such extended HLA-I epitopes in tumour immunity, and how they would be recognised by T-cell receptors (TCR) remains unclear. Here we show that the structures of two distinct TCRs (TRAV4+TRAJ21+-TRBV28+TRBJ2-3+ and TRAV4 + TRAJ8+-TRBV9+TRBJ2-1+), originating from a polyclonal T-cell repertoire, bind to HLA-B∗07:02, presenting a 13-amino-acid-long tumour-associated peptide, NY-ESO-160-72. Comparison of the structures reveals that the two TCRs differentially binds NY-ESO-160-72-HLA-B∗07:02 complex, and induces differing extent of conformational change of the NY-ESO-160-72 epitope. Accordingly, polyclonal TCR usage towards an extended HLA-I restricted tumour epitope translates to differing TCR recognition modes, whereby extensive flexibility at the TCR-pHLA-I interface engenders recognition.",
keywords = "adaptive immunity, antigen processing and presentation, tumour immunology, x-ray crystallography",
author = "Chan, {Kok Fei} and Gully, {Benjamin S.} and Stephanie Gras and Beringer, {Dennis X.} and Lars Kjer-Nielsen and Jonathan Cebon and James McCluskey and Weisan Chen and Jamie Rossjohn",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41467-018-03321-w",
language = "English",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide. / Chan, Kok Fei; Gully, Benjamin S.; Gras, Stephanie; Beringer, Dennis X.; Kjer-Nielsen, Lars; Cebon, Jonathan; McCluskey, James; Chen, Weisan; Rossjohn, Jamie.

In: Nature Communications, Vol. 9, No. 1, 1026, 01.12.2018.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide

AU - Chan, Kok Fei

AU - Gully, Benjamin S.

AU - Gras, Stephanie

AU - Beringer, Dennis X.

AU - Kjer-Nielsen, Lars

AU - Cebon, Jonathan

AU - McCluskey, James

AU - Chen, Weisan

AU - Rossjohn, Jamie

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Human leukocyte antigen (HLA)-I molecules generally bind short peptides (8-10 amino acids), although extended HLA-I restricted peptides (>10 amino acids) can be presented to T cells. However, the function of such extended HLA-I epitopes in tumour immunity, and how they would be recognised by T-cell receptors (TCR) remains unclear. Here we show that the structures of two distinct TCRs (TRAV4+TRAJ21+-TRBV28+TRBJ2-3+ and TRAV4 + TRAJ8+-TRBV9+TRBJ2-1+), originating from a polyclonal T-cell repertoire, bind to HLA-B∗07:02, presenting a 13-amino-acid-long tumour-associated peptide, NY-ESO-160-72. Comparison of the structures reveals that the two TCRs differentially binds NY-ESO-160-72-HLA-B∗07:02 complex, and induces differing extent of conformational change of the NY-ESO-160-72 epitope. Accordingly, polyclonal TCR usage towards an extended HLA-I restricted tumour epitope translates to differing TCR recognition modes, whereby extensive flexibility at the TCR-pHLA-I interface engenders recognition.

AB - Human leukocyte antigen (HLA)-I molecules generally bind short peptides (8-10 amino acids), although extended HLA-I restricted peptides (>10 amino acids) can be presented to T cells. However, the function of such extended HLA-I epitopes in tumour immunity, and how they would be recognised by T-cell receptors (TCR) remains unclear. Here we show that the structures of two distinct TCRs (TRAV4+TRAJ21+-TRBV28+TRBJ2-3+ and TRAV4 + TRAJ8+-TRBV9+TRBJ2-1+), originating from a polyclonal T-cell repertoire, bind to HLA-B∗07:02, presenting a 13-amino-acid-long tumour-associated peptide, NY-ESO-160-72. Comparison of the structures reveals that the two TCRs differentially binds NY-ESO-160-72-HLA-B∗07:02 complex, and induces differing extent of conformational change of the NY-ESO-160-72 epitope. Accordingly, polyclonal TCR usage towards an extended HLA-I restricted tumour epitope translates to differing TCR recognition modes, whereby extensive flexibility at the TCR-pHLA-I interface engenders recognition.

KW - adaptive immunity

KW - antigen processing and presentation

KW - tumour immunology

KW - x-ray crystallography

UR - http://www.scopus.com/inward/record.url?scp=85044217316&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-03321-w

DO - 10.1038/s41467-018-03321-w

M3 - Article

VL - 9

JO - Nature Communications

T2 - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1026

ER -